Editorial Series
Search for
Go
Sort by 
Page
Showing 1 - 10 of 10 documents.
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Bob Harrington
Nov 6, 2009 09:50 EST
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
Editorial series
Clinical research: Comparing regulatory pathways in US and UK
Oct 30, 2009 12:35 EDT
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Peter Sleight
2 COMMENTS - Oct 13, 2009 10:15 EDT
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.
Editorial series
ACC and AHA: Leadership in today's healthcare environment
Sep 15, 2009 14:10 EDT
Dr Robert Califf sits down with Drs Alfred Bove, Jack Lewin, and Clyde Yancy and AHA CEO Nancy Brown to talk about the ACC and the AHA and their role in the debate on healthcare reform.
The Cardiology Show
Best of Barcelona: PLATO and RE-LY
Sep 2, 2009 11:15 EDT
Dr Valentin Fuster returns to the city where he was born for a scintillating discussion with Drs Fox, Gershlick, Marrouche, Messerli, Spaulding, Vergheugt, Virmani, and Yancy about the miracle of RE-LY and the striking success of ticagrelor in the PLATO study.
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Steve Nissen
1 COMMENT - Jun 1, 2009 10:20 EDT
Join Dr Robert Califf for a probing and personal interview with Dr Steve Nissen, about his activist days at the University of Michigan and the development of IVUS, to how he ended up at the Cleveland Clinic and what he thinks about the future of medicine in America.
The Cardiology Show
ACC 2009: From the eye of the storm in Orlando
Apr 2, 2009 15:35 EDT
Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.
Ten years in review
Reviewing 10 years of cardiology news
1 COMMENT - Dec 3, 2008 14:30 EST
As theheart.org enters its 10th year join editor-in-chief, Dr Eric Topol, and his guests for a second look at the top news from the past decade. Throughout the coming months, we'll revisit the most important story from each of the last 10 years and ask: How has practice been affected? With time and perspective, what has changed and what have we learned?
Cardiology panels
SYNTAX at one year: Deciphering the data
Oct 3, 2008 13:40 EDT
Drs Antonio Colombo and Renu Virmani talk about the one-year results of the SYNTAX trial, the importance of understanding registries, and the complex issue of clopidogrel duration with drug-eluting stents in a discussion moderated by heartwire journalist Shelley Wood.
Cardiology panels
Getting the lowdown on HORIZONS
Jan 15, 2008 15:49 EST
Getting the lowdown on HORIZONS

Drs Keith Fox and Gregg Stone go into the details of this practice-changing trial as they address concerns about acute stent thrombosis and talk about ways to improve outcomes, in a discussion moderated by Dr James Ferguson.

button
Previews
Featured programs
Poll
Would you feel comfortable stopping clopidogrel for 5-10 days if a patient with a DES required surgery?
See: Shelley Wood. Five-to-10 day cessation of thienopyridine likely safe for surgery if aspirin maintained, post-DES.
Yes
No

Vote
Inside: Thrombosis Risk
More
More
Thrombosis Risk
North American Thrombosis Forum (NATF)
3 COMMENTS - Jan 12, 2009 02:02 EST
NATF's vision is to improve patient care, outcomes, and public health by utilizing a multidisciplinary approach to advance thrombosis research and education. NATF's legacy will be the improvement of patient care, outcomes, and public health by supporting thrombosis-related programs, such as novel research projects, innovative educational programs, public policy initiatives, regulatory issues and advocacy. NATF also seeks to broaden training opportunities for physicians, scientists, and other health professionals.